Getting right with God -- abcGod.net
abcGod.net
abcGod.com
&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&
&&&&&&& & &&&
&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&
Getting right with God
Luke 15:10
Do you know where you will spend eternity? Are you
going to make it into heaven or is there a chance you
might end up in hell?
God smiles on us when we want to learn about Him and
His ways. Ignoring Him is not a good idea. Many people
have their own beliefs about God and how to get right
God doesn't change His ways to our ways any more than adults
change to a child's ways. Assumptions
and wishful thinking are among the worst ways to
conclude anything about anyone, especially God. We
need to learn what God says about Himself
because the greatest future event for every soul is
accountability to God.
In this age of political
correctness and moral relativism, God has not changed.
Let's take a look at what God has to tell those who
make incorrect assumptions about Him.
Job 38:1-4 Then the
LORD answered Job out of the whirlwind, and said:
“Who is this
who darkens counsel by words without knowledge?
Now prepare&I will question
you, and you shall answer Me. “Where were you when
I laid the foundations of the earth?&Tell Me, if
you have understanding.
It would be good to now pray this short prayer: Father in
Heaven, please give me
understanding to learn the truth about You and Your
ways. In Jesus' name, thank You.
unwise to not fear that we will be held accountable for our sins or that
they are insignificant in comparison to the sins of
criminals who make the news. People are not God's
standard for righteousness ... Jesus is.
God knows all our
Matthew 10:26
&... for there is
nothing concealed that will not be revealed, or hidden
that will not be known.&
What does sin produce?
Romans 6:23
For the wages of sin is death [hell]; but
the free gift of God is eternal life through Christ
Jesus our Lord.
Our Universal Dilemma
We don't need to go
too far down the list of the Ten Commandments to learn
we are guilty of sin. For example: You shall not use
the Lord's name in vain. Honor your mother and father.
You shall not commit adultery/fornication. You shall
not steal. You shall not lie.
Our sin separates us from our Holy Creator. Lying to
ourselves about our innocence is self defeating.
If someone has the
cure for cancer and keeps it to them self, the world
would call them cruel. But humanity has a greater and
more universal problem than cancer. It is sin. Sin is
what keeps us out of God's sinless heaven and condemns
us to sinful hell. And Jesus warned us that more
people are ending up in
hell than heaven:
Matthew 7: 13-14
&Enter thr for the gate is
wide and the way is broad that leads to destruction
[hell], and there are many who enter through it.
For the gate is small and the way is narrow that leads
to life [heaven], and there are few who find
Many people think we
get into heaven by doing good things. But doing good
things does not erase the bad things we have done.
How we get sin removed from our record
Unlike cancer,
the cure for sin is accessible to all and is free!
Most people already know these three very important
1.& Jesus died
on the cross for our sins.
2.& Jesus shed
much blood when He was crucified.
suffered this very painful death voluntarily for us (He did
not have to do this for Himself--He is sinless).
Jesus paid the price for our
sins because we are unable to pay the penalty. If we could
make it into heaven on our own by doing good things or
by some religious exercises, then Jesus was a fool …
He suffered voluntarily for nothing.
But Jesus is no fool! He paid the greatest price anyone paid for
anything and that is for our souls so we could make it
into heaven!
Ephesians 2:8-9
For it is by grace you have been saved, through
faith—and this not from yourselves, it is the gift of
God—not by works, so that no one can boast.
Now you can understand why God is
who ignore this most costly and precious gift that He is offering to us for
free. (Think of how you would feel toward
who rejects/ignores the most costly gift you could give.)
The significance of the blood of Jesus
The Bible tells us that the blood of Jesus washes our
sins away, similar to how a delete key erases the record in
computer file. This means when we (true Christ followers) are
called up to give account at the
, our record will have no sin on it because
the blood of Jesus washed it off!
I hope you can appreciate the magnitude of this.
Hebrews 13:12 And so Jesus also suffered ... to
make the people holy through his own blood.
Revelation 1:5 And
from Jesus Christ, … Him that loved us, and washed us
from our sins in His own blood,
John 14:6 &Jesus said ..., 'I am the way, and the
truth, no one comes to the Father, but
through Me.'&
John 3:18 [Jesus speaking] &He who believes in Him
is not judged; he
who does not believe has been judged already, because
he has not believed in the name of the only begotten
Son of God.
John 5:22-24 [Jesus speaking] &For not even the
Father judges anyone, but He has given all judgment to
the Son, so that all will honor the Son even as they
honor the Father. He who does not honor the Son does
not honor the Father who sent Him. &Truly, truly, I
say to you, he who hears My word, and believes Him who
sent Me, has eternal life,
and does not
come into judgment, but has passed out of death
into life.
I hope you pray the following
prayer with deep sincerity. If you do, you too can
have confidence that you are in right standing with
your Creator and will make it into heaven.
1 John 5:13 These things I
have written to you who believe in the name of the Son
of God, so that you may know that you have eternal
Prayer to get right
Dear Father in heaven, I
confess that I am a sinner and my sins have separated
us. I want to be in a right relationship with You. I ask You to
help me remember my sins so that I may repent of them
and come clean. I sincerely repent of my sins and ask
for Your mercy to forgive me of my sins. I accept
Jesus' crucifixion, His shed blood and rising from the
His payment for my sins. I ask for Your Holy
Spirit to come into my heart to guide my thoughts and
actions and to help me stay away from my sinful ways. Thank You in the name of
my Savior Jesus
Christ, Amen!
Luke 15:10
and pray to
Find a good Bible
free to print this page, mark it up and call
me with whatever questions or doubts you may have.
I also eagerly accept prayer requests. You can get more information by
listening to a quality
with good music and good news.
And don't forget to tell others about this most
important information.
For links to good
Bible-Believing Churches
With the love of Jesus Christ,
Ro.n Jasniow.ski
www.abcGod.net
Palatine, Illinois& 60074
Ro.n Jasniow.ski
abcGod.com
Getting Right With God
abcGod.net
Plan of salvation
What Does Born Again Mean?
God's Plan of Salvation
How to Get Peace with God
How to make it into heaven
How to Have Peace with God
Being Right With God
Do not waste your life
How to connect with God
How Do I Get Right With God
What Are Born Again Christians?
How to come to Christ
How Do You Get Saved?
How to get to know God
Criteria needed to spend eternity with God
Knowing God
How Can I Make Myself Right With God?
How to know God
How To Become Born Again
How to Get Right with God Jesus
How to Get Yourself Right with God
How to Get Your Heart Right with God
How to Truly Get Right with God
How to Get Your Heart Right with God
How to Get My Life Right with God
How to Become a Christian
How To Get In A Right Relationship With God
How to get back right with God
How to be right before God
Making It Right With God
Hot to get into heaven
How do you get right with God?
How to come to Jesus
How to Get Right with God and make it into heaven
How to Get Right with God and get into heaven
How to get to heaven
How to Get Saved
Connect with God
&How To Get Right With God&
Get Your Heart Right With God
Getting to know God
Relationship with God
How can I be saved
Relating with God
How to Get Right with God Again
Salvation Prayer
How to have a relationship with God
What Is Born Again
Connecting with GodA Chinese herbal formula, Yi-Qi-Fu-Sheng, inhibits migration/invasion of colorectal cancer by down-regulating MMP-2/9 via inhibiting the activation of ERK/MAPK signaling pathways | SpringerLink
This service is more advanced with JavaScript available, learn more at http://activatejavascript.org
A Chinese herbal formula, Yi-Qi-Fu-Sheng, inhibits migration/invasion of colorectal cancer by down-regulating MMP-2/9 via inhibiting the activation of ERK/MAPK signaling pathwaysWanli DengHua SuiQiaolin WangNana HeChunyan DuanLiang HanQi LiMing LuShuqin LvOpen AccessResearch article
Part of the following topical collections:A Chinese herbal formula, Yi-Qi-Fu-Sheng (YQFS), has long been employed clinically to treat cancer patients. We aimed to determine its effectiveness as a treatment method for colorectal cancer. We investigated the therapeutic effects of YQFS on colorectal cancer, as well as the underlying mechanisms, which have not previously been explored.First, YQFS was extracted and chemically characterized. We then tested the effects of YQFS on proliferation and migration by MTT and transwell migration assays in vitro. Mouse xenograft models of colorectal cancer were established by inoculation with HCT-116 cells, and mice received one of three oral doses (200, 400 and 800 mg/kg/day) to evaluate the effects of YQFS extract. Metalloproteinase-2/9 (MMP-2/9) expression in mice was evaluated by gelatin zymography assay. Apoptosis was evaluated by flow cytometry (FCM) analysis in vitro and by TUNEL assay in vivo. ERK and p-ERK expression were evaluated by western blot analysis at the protein level in vitro, and by quantitative RT-PCR at mRNA level in vivo.Our results show that YQFS significantly inhibits colorectal cancer cell proliferation and induces apoptosis and cell cycle arrest at the G1- and S-phase in HCT-116 cells. Furthermore, YQFS effectively retards tumor cell migration and invasion by inhibiting metalloproteinase-2/9 (MMP-2/9) expression, both in vitro and in vivo. Moreover, YQFS had an inhibitory effect on tumor growth in vivo, and induced apoptosis through the inhibition of the ERK1/2 pathway both in vitro and in vivo.These findings demonstrate that YQFS extract has an anti-tumor effect in colorectal cancer, which could be attributed to ERK1/2-dependent inhibition of MMP-2/9 expression.Colorectal cancer Invasion and migration Metalloproteinase-2/9 Extracellular signal-regulated kinase Yi-Qi-Fu-Sheng herbal formula Colorectal cancer has an incidence of approximately 150,000 per year in the United States and is the third leading cause of cancer-related deaths in both men and women[]. Although surgery, chemotherapy and radiotherapy have been the mainstay of colorectal cancer treatment, traditional Chinese medicine (TCM) has the advantage of reducing cancer therapy-induced toxicity and is a popular form of complementary and alternative medicine (CAM) in China[]. In recent years, with increased popularity with patients in China, the modified classic formula has been shown to further minimize the side effects of surgery, radiation and chemotherapy[], increase immune function[] and improve survival[].Mitogen-activated protein kinases (MAPK), which belong to a large family of serine-threonine kinases, form major cell proliferation signaling pathways from the cell surface to the nucleus[]. The ERK/MAPK pathway is one of the most important pathways for cell proliferation, and several key growth factors and proto-oncogenes transduce signals that promote growth and differentiation through this cascade[]. Several lines of evidence suggest that the ERK/MAPK pathway, but not the JNK pathway or the p38 MAPK pathway, is a major regulator of cell proliferation in colorectal cancer[]. During oncogenic transformation, colorectal cancer cells escape normal growth and differentiation control mechanisms and acquire the ability to invade surrounding tissues and organs. Activation of ERK1/2 culminates in the phosphorylation of transcription factors that regulate specific genes to increase cell proliferation and inhibit apoptosis[].Traditional Chinese prescriptions and formulae, which are based on TCM principles, have been identified as effective anti-cancer drugs in for example breast carcinoma[], gastric cancer[] and colorectal cancer[]. YQFS, a Chinese herbal formula, is composed of six herbs: Dang-shen (Codonopsis pilosula), Bai-zhu (Atractylodes macrocephala), Fu-Ling (Poria), Gan-cao (Radix Glycytthizae), Rou-dou-kou (Myristica fragrans) and Ba-yue-zha (Fiveleaf Akebia fruit), in a ratio of 4:3:4:3:3:3. The components of the herbal formula are mostly derived from the classic formula “Si-Jun-Zi Tang” in TCM, which has a long history in treating deficiencies of the spleen and qi in cancer patients.Recent clinical studies suggest that Si-Jun-Zi Tang herbal formula possesses anti-tumor and immune enhancing properties in colorectal cancer[]. Modification of the Si-Jun-Zi Tang formula has been shown to have a wide range of immunopotentiating effects. As an example, administering two drugs, Rou-dou-kou and Ba-yue-zha, found in the Si-Jun-Zi Tang formula, exhibited anti-cancer effects and provided an advantage above using chemotherapy alone[, , ].Although the anti-cancer effects of YQFS herbal formula have previously been demonstrated, the underlying mechanisms, in colorectal cancer, remain unknown. In this study, our objective was to elucidate the effect and the molecular mechanism(s) of the Chinese herbal formula, YQFS, in colorectal cancer cells.Human colorectal cancer HCT-116 cells were obtained from the cell bank of the Chinese Academy of Sciences (CAS) and maintained in RPMI 1640 medium supplemented with 10% (v/v) heat-inactivated fetal calf serum, 2 mM glutamine, 100 units/ml penicillin, and 100 μg/ml streptomycin (Invitrogen, Carlsbad, CA) at 37°C in a 5% CO2 humidified atmosphere.All crude drugs (defined as a dried, unprocessed plant, and referring to one that was or is an official drug plant or the source of a refined drug substance) of YQFS were purchased from a local herbal medicine market (Xinjiang, China). All components were deposited at the herbarium located in the College of Pharmacy, Xinjiang Medical University. Briefly, Dang-shen, Bai-zhu, Fu-Ling, Gan-cao, Rou-dou-kou and Ba-yue-zha were mixed at a ratio of 4:3:4:3:3:3. YQFS extracts were prepared according to a previously validated method[]. The mixture (300 g) was homogenized to a fine powder and then extracted twice in a reflux condenser for 2 h with 75% ethanol in a heated water-bath. The pooled extract was filtered to remove debris, and the ethanol was removed by rotary evaporation under reduced pressure. The concentrated extract was then dried by lyophilization to obtain the YQFS extract at a yield of 190 g. According to HPLC analysis of the YQFS extract, the ratio of crude drug to ethanol extract was 1 g/0.633 g. The extract was stored at 4°C, dissolved in distilled water and diluted with physiologic saline for the animal tests.Drug sensitivity was determined using the MTT assay. Briefly, cells were trypsinized and plated out into 96 well plates at a density of 3 × 103 cells per well. Cells were cultured overnight and re-fed with fresh medium at various concentrations of YQFS for 24 h. Thereafter, 50 μl 3-(4,4-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma-Aldrich, St. Louis, MO) in PBS was added to each well, incubated for 4 h at 37°C and the formazan crystals that formed were dissolved in 150 μl dimethyl sulfoxide. The optical density was recorded at 570 nm on a microplate reader (Bio-Rad, Hercules, CA).Cells were seeded in 6-well plates (4 × 105/well). After 24 h, three dose concentrations of YQFS (obtained from the result of YQFS IC10 in the MTT assay) were added. Flow cytometry was used to detect apoptosis by determining the relative amount of Annexin V-FITC-positive-PI-negative cells, as previously described. Unstained cells, cells stained with Annexin V-FITC alone, and cells stained with propidium iodide alone were used as controls. Singly stained cells were used to adjust electronic compensation on FL1 and FL2 channels.Dual staining for a-SMA and TUNEL was undertaken in representative liver sections to localize apoptotic hepatic stellate cells (HSCs). The sections were blocked with Dako double stain blocking solution for 3 min. The primary antibody for a-SMA, in a dilution of 1:1000, was added and incubated for 30 min at room temperature. Histofine labeled polymer (Nichirei, Tokyo, Japan) was added for 20 min at room temperature. The sections were then incubated with the substrate chromogen nitro-blue tetrazolium (NBT) for 5 min. The number of apoptotic HSCs were counted by viewing specimens under the microscope. The apoptosis index was defined as the number of apoptotic cells in every hundred cells counted.Migration assays were performed following a standard protocol wound repair assay[]. Briefly, cells were cultured in standard conditions, as described above, to 70%-80% confluency after treatment with YQFS. The monolayers were incubated and wounded in a line across the well with a standard pipette tip. The wounded monolayers were washed twice with phosphate-buffered saline (PBS) and incubated with serum-containing medium. The rate of wound closure was measured and photographed over 24 h. This allows imaging of both wound edges using the 10× objective.Whole cell lysate for SDS-PAGE and western blot analysis for ERK expression was prepared as previously reported[]. To prepare the lysates from dissected in vivo tumors, samples were snap frozen in liquid nitrogen immediately after sacrificing the animals and stored at -80°C. The lysate was incubated on ice in immunoprecipitation assay buffer for 2 h before being homogenized using a mortar and pestle. The homogenized sample was centrifuged and the supernatant was collected and stored at -80°C. Protein quantification and western blotting for ERK were done as previously reported[]. Equal loading was confirmed with β-actin (0.1 μg/mL, Sigma Chemical). Densitometric analysis was done using Scion Imaging software (Scion Corporation), using total ERK or β-actin as a control for each sample.Male athymic nude mice (NCr-nu) were purchased from Sino-British SIPPR/BK lab Animal Ltd., Co (Shanghai, China, license No. SCXK ) and maintained under specific pathogen-free conditions for the studies. All animal protocols were approved by the Institutional Animal Use and Care Committee. All experiments and animal care protocols were approved by the Shanghai Medical Experimental Animal Care Commission in accordance with the Provision and General Recommendation of Chinese Experimental Animals Administration Legislation. The mice used in these experiments were 8–12 weeks old.HCT116 cells were grown in culture and then detached by trypsinization, washed, and resuspended in HBSS. Next, 0.2 mL of the resuspended cells (1.0 × 106) were subcutaneously injected into the athymic nude mice to initiate tumor growth. Tumors were allowed to reach an average size of 100 mm3, after which mice were randomized into 4 groups (n = 10 per group). Mice in group 1 were administered distilled water daily, which served as a vehicle control. Mice in group 2 were given 5-fluorouracil (5-FU) intraperitoneally, every 2 days, at a dosage of 0.5 mg/kg, half the maximum tolerated dose (MTD) of 5-FU, as previously described[]. Mice in groups 3,4 and 5 received YQFS at a daily dose of 200, 400 or 800 mg/kg respectively, by intragastric administration for 19 days. In the clinical practice of Chinese herbal medicine, YQFS is usually prescribed at a daily dose of 400 mg herbal materials. When this human dose was converted into an animal dose (at an extraction yield of 2.5%, for a person weighing 60 kg, and a conversion factor of 12.33 between humans and mice), it was equivalent to the middle dose (400 mg extract/kg) used in this study.Body weight and tumor growth were measured every 2 days. Tumor growth was determined by measuring the major (L) and minor (W) diameter with a caliper. The tumor volume was calculated according to the following formula: tumor volume = π/6 × L × W2. At the end of experiment, the animals were anesthetized with pentobarbital, and the tumor tissue was removed and weighed.All tumor groups were plated onto 12-well culture plates and made quiescent by incubation in serum-free DMEM/F-12 for 24 h. The culture medium was collected and centrifuged at 10 000 × g for 5 min at 4°C to remove cell debris. MMP-2/9 expression was analyzed as previously described[]. The gel analysis function in ImageJ () was used to quantify protease activity bands by densitometry. Values are reported in Relative Intensity Units (RIU).For RNA isolation, tumors were homogenized and suspended, and RNA was extracted using the RNAspin Mini Kit (GE Healthcare, Waukesha, WI, USA) according to the manufacturer’s instructions. For cDNA synthesis, 1 μg of total RNA was reverse-transcribed using oligo-dT primers and the Superscript Amplification System (Life Technologies, Carlsbad, CA, USA). Quantitative RT-PCR was carried out using SYBR Green PCR Master Mix (Life Technologies). The PCR amplification program consisted of an initial polymerase activation at 94°C for 5 min, followed by 35 cycles at 94 C for 30 s, 59.5°C for 40 s and 72 C for 30 s for VEGF. Amplification of GAPDGH, a relatively invariant internal reference RNA, was performed in parallel, and cDNA amounts were standardized to equivalent GAPDGH mRNA levels. Oligonucleotide primers for VEGF and GAPDGH were as follows: Oligonucleotide sequence (5’-3’) of ERK1/2 (188 bp), F: 5’-CCTGCTGGACCGGATGTTA-3’, R: 5’-GTCTCTTGGAAGATCAGCTC-3’, Oligonucleotide sequence (5’-3’) of GAPDH (306 bp), F: 5’-ACCCACTCCTCCACCTTTGA-3’, R: 5’-CTGTTGCTGTAGCCAAATTCGT-3’. mRNA expression was determined by real-time PCR using the TaqMan method as previously described[].All values were expressed as the mean ± S.D. and analyzed by one-way analysis of variance (ANOVA) followed by Duncan’s Multiple Range Test using SPSS version 13.0 a p-value of less than 0.05 was considered significant.We used a simple and accurate HPLC method for the simultaneous separation and determination of six components to evaluate the quality of YQFS. We then tested their effects on the growth of the HCT-116 human colorectal cells in vitro. As shown in Figure , after treatment for 24 h, YQFS induced a dose-dependent decrease in cell viability in HCT-116 cells, as analyzed by MTT assay. HCT-116 cells showed a significantly reduced rate of cell growth.
Figure 1 Effect of YQFS on the inhibition of HCT-116 cells. Cells were treated with various concentrations of YQFS and analyzed by MTT assay. The IC50 value is 34.09 mg/ml. For the dose–response analysis, we chose three doses below the IC50 value, and turned into a multiple relationship. We then tested whether YQFS affected cell cycle progression. The results showed a significant decrease in the number of cells in the proliferative G1- and S-phases and a significant increase in the number of cells in the G2-phase after 24 h of treatment with YQFS (Figure A). These results indicate cell cycle arrest at the S-phase after treatment of HCT-116 cells with YQFS. To confirm these results, we evaluated the effects of YQFS on apoptosis in HCT-116 cells. We observed a marked increase in both early and late stage apoptosis, as assessed by flow cytometry, in HCT-116 cells after YQFS treatment compared with control cells (Figure A). We then evaluated the effects of YQFS on apoptosis in HCT-116 cells by using annexin V-FITC and PI staining. Again, we saw a marked dose-dependent increase in both the early and late stage apoptosis, as assessed by flow cytometry, in HCT-116 cells after YQFS treatment, compared with control cells (Figure B).
Figure 2 The Effect of YQFS on apoptosis and the cell cycle in HCT-116 cells. (A) Flow cytometry analysis of the cell cycle distribution of cultured HCT-116 cells with PI staining following 24 h exposure of cells to YQFS. Detection of apoptosis with Annexin V-FITC/PI binding to HCT-116 cells. Viable cells (Annexin V-/PI-) are located in the lower left, apoptotic cells (Annexin V+/PI-) in the lower right, post apoptotic secondary necrotic cells (Annexin V+/PI+) in the upper right and primary necrotic cells (Annexin V-/PI+) in the upper left quadrants, respectively. The numbers in each quadrant are the percentages of cells in question. (B) Distribution of HCT-116 cells’ cycle indicated by PI staining. The values shown are the mean ± SEM of 3 experiments. **P & 0.01 vs. the control. We examined whether YQFS extract attenuated the motility of HCT-116 cells using the scratch wound repair assay. Cell migration increased after 24 h for the control group, but was substantially reduced when lower dose YQFS exerts was present (Figure ). We also tested the effect of middle and higher dose of YQFS extract, the result showed a 40%-60% delay in wound closure after treatment for 24 h (Figure ). These results suggest that YQFS inhibited migration/invasion in human colorectal cancer HCT-116 cells in a dose-dependent manner.
Figure 3 Effect of YQFS on cell migration in a scratch wound repair assay. Scratch-wound motility assays were carried out to detect wounded monolayers in HCT-116 cells. The effects of various concentrations of YQFS (8 mg/ml, 16 mg/ml and 32 mg/ml) on the migration of human aortic smooth muscle cells (HASMCs) at 0 h (upper row of images) and 24 h (lower row of images). Cell migration increased in the control and this effect was attenuated with the addition of YQFS. To determine whether the MAPK pathways are involved in the anti-invasion and metastasis of tumor progression, the expression of JNK, ERK and p38 phosphorylation was examined in HCT-116 cells by western blotting. The results showed that the ERK signal transduction pathway was activated in HCT-116 cells. We observed decreased phosphorylation of ERK (p-ERK) in HCT-116 cells (Figure ), but saw no significant effect in the levels of p-JNK or p-p38 (data not shown) after 24 h of YQFS treatment. These observations suggest that ERK, but not JNK or the p38/MAPK pathway, was inhibited by YQFS thus mediating anti-migration/invasion in human colorectal cancer HCT-116 cells.
Figure 4 The effect of YQFS on the expression of ERK and p-ERK in HCT-116 cells. Western blotting assays were carried out to detect the activation of ERK in HCT-116 cells. HCT-116 cells were treated with YQFS at 8 mg/ml, 16 mg/ml and 32 mg/ml for 24 h respectively. Western blotting with was performed with an anti-β-actin antibody to ensure equal loading of proteins in each lane. The bolts were photographed and quantitated for each sample and the data are from three independent experiments. In light of our in vitro data on the effect of YQFS in sensitizing colorectal cancer cells, we examined the therapeutic potential of YQFS in vivo. Based on our clinical data and preliminary experiments, mice were administered 12.33 times the dose given to human patients. Administration with herbal mixtures did not cause weight loss, decreased activity, or changes in fur quality of the rabbits (data not shown).The in vivo anti-tumor effect of YQFS was evaluated by measuring tumor weight and volume in colorectal cancer xenograft mice, while adverse effects were determined by measuring any body weight gain. As shown in Figure , H-YQFS treatment resulted in a 51% decrease in tumor volume compared with the control (997 ± 85 mm3 or 450 ± 49 respectively). Consistent with the tumor volumes, there was a 54% decrease in the tumor weights per mouse in the H-YQFS-treated group compared with the control group (1.06 ± 0.09 or 2.29 ± 0.30 grams respectively) as seen in Table . These suppressive effects of YQFS were dose-dependent. However, administration of different doses of YQFS (L-YQFS, M-YQFS and H-YQFS) had no effect on body weight gain in experimental animals (Table ). Taken together, this suggests that YQFS is potent suppressor of colorectal tumor growth in vivo, with no apparent signs of toxicity.
Figure 5 The effect of YQFS on tumor growth in vivo. After mice were injected with HCT-116 cells (2 × 107), they were divided into five groups: Vehicle, L-YQFS (200 mg/kg), M-YQFS (400 mg/kg), and H-YQFS (800 mg/kg) were administered orally, each day for 18 days. The 5-Fu group was injected 5-Fluorouracil once every 2 days. Values were presented as mean ± SD., (n = 10). Table 1 The effects of YQFS on body- and tumor weight of experimental animals (means ± SD) GroupDoses (mg/kg)nBody weight(g)Tumor weight(g)InitialFinalControl-1020.00 ± 1.0024.00 ± 1.002.29 ± 0.30L- YQFS2001018.00 ± 1.0023.00 ± 0.501.88 ± 0.14M- YQFS4001019.00 ± 1.0023.00 ± 1.001.46 ± 0.11*H- YQFS8001020.00 ± 1.0024.00 ± 0.501.06 ± 0.09**5-Fu0.51021.00 ± 1.0023.40 ± 2.000.99 ± 0.08**To determine whether the inhibitory effect of YQFS on cancer growth is related to cell proliferation and apoptosis, we examined the YQFS pro-apoptotic and anti-proliferative activities in colorectal cancer mice via immunohistochemical (IHC) staining for TUNEL and PCNA. The data in Figure
shows that the apoptotic index for H-YQFS was 44.24 ± 4.84%, 3.29 times that of the control (13.45 ± 1.09). These results are in agreement with our in vitro apoptosis results, which showed that YQFS significantly induced HCT-116 cell apoptosis in a dose-dependent manner. These data demonstrated that YQFS inhibited the proliferation of colorectal cancer cells and promoted cell apoptosis in vivo.
Figure 6 The effect of YQFS on apoptosis in vivo . A TUNEL assay was performed to detect apoptosis in vivo as described in the materials and methods section. The relative fold increase in apoptosis index is plotted as a graph. Each value is presented as the mean ± SD as determined from three independent experiments. *P & 0.05 vs. **P & 0.01 vs. the control group. Based on the preliminary experiments in vitro, we examined the expression of the angiogenic factors, MMP-2 and MMP-9, in tumors harvested from the various therapy groups (Figure ). Both MMP-2 and MMP-9 expression was significantly lower in the YQFS-based therapy groups, suggesting that its antitumor effect may be mediated, in part, by downregulation of MMP-2/9 expression.
Figure 7 The Effect of YQFS on the expression of MMP-2/9 in vivo . Gelatin Zymography analysis of MMP-2/9 in vivo, as described in the materials and methods section. The relative fold change in expression of MMP-2/9 is plotted as a graph. Each value is presented as the mean ± SD as determined from three independent experiments. *P & 0.05 vs. **P & 0.01 vs. the control. Based on the preliminary experiments in vitro, we therefore examined the effect of YQFS on ERK mRNA levels in tumor tissue using quantitative RT-PCR. As shown in Figure , YQFS decreased ERK mRNA levels in a dose-dependent manner in mice tumors, with H-YQFS treatment resulting in a threefold decrease in ERK mRNA levels with respect to the control. The results shown are similar to that of MMP-2/9.
Figure 8 The effect of YQFS on ERK mRNA levels in vivo . Real-time quantitative PCR was performed to detect ERK mRNA in vivo. The data represented here were calculated from the means ± SD from triplicate experiments. **P & 0.01, vs. the control group. In this study, we demonstrated for the first time that YQFS inhibits tumorigenesis and cancer metastasis in colorectal cancer both in vitro and in vivo. Our results indicate that YQFS can modulate the ERK/MAPK pathway, and its downstream factors, by targeting ERK phosphorylation. We show that the growth of colorectal cancer cells is repressed by YQFS-induced apoptosis and inhibition of migration/invasion. In vivo, YQFS induced a significant delay in tumor growth, which could be mediated by decreased expression of MMP-2/9 via the ERK pathway. Our research therefore suggests that this Chinese Herbal medicine, YQFS, could inhibit migration/invasion of colorectal cancer by down-regulating MMP-2/9 via inhibition of the ERK/MAPK signaling pathway. YQFS therefore has previously undiscovered therapeutic potential for treating colorectal cancer.In Asia, the incidence of colorectal cancer has become a national public health problem[, ]. Despite advances in surgical and chemotherapeutic approaches, the resistance of colorectal cancer cells to traditional cytotoxic agents is a major obstacle in clinical cancer therapy, with most colorectal cancer patients eventually succumbing to the disease[]. Therefore, novel therapeutic approaches for colorectal cancer are needed.With the use of Traditional Chinese prescriptions and formulae, which are based on TCM principles, these agents have been identified as effective anti-cancer drugs in cancer patients, such as breast carcinoma, gastric cancer and colorectal cancer. Our previous clinical studies have demonstrated that YQFS prolongs the overall survival for stage IV colorectal cancer patients. It is now clear that administering herbal extracts may improve therapeutic outcomes among cancer patients. We therefore conducted a series of experiments to examine the potential mechanisms responsible for the therapeutic effects of YQFS.To quantitate the effects of YQFS on cell growth, cell viability was assayed by reduction of MTT for 24 h with various concentrations of nimbolide. We found that YQFS treatment inhibited growth in colorectal cancer HCT-116 cells in a dose-dependent manner (Figure ). We then investigated whether YQFS-induced inhibition of cell growth was due to perturbation of the cell cycle. Cell phase distribution analysis showed an accumulation of cells in the S-phase upon treatment with YQFS (Figure B), indicating that YQFS inhibits tumor cell proliferation and exerts its growth inhibitory actions through alterations in the cell cycle, and by inducing apoptosis.It is well accepted that invasion and metastasis are integral parts of tumor progression and, investigators have reported that Physalis angulata markedly inhibits migration and invasion of highly metastatic HSC-3 cells, as shown by wound-healing repair- and trans-well-assays[]. In our study, HCT-116 cell lines showed slower migration compared with the control after treatment with YQFS, judged by a scratch-wound motility assay (Figure ). These data suggest that YQFS may modulate colorectal cancer invasion via altered cell motility.The MAPK pathway represents one of the signaling cascades that link external stimuli to the transcriptional regulation of various molecules including those related to tumor-invasion and -metastasis. In mammals, three major MAPK pathways have been identified: extracellular-signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 mitogen-activated protein kinase (p38 MAPK)[]. There is growing evidence to support a strong correlation between ERK and invasive and metastatic potential in colorectal cancer[]. In this study, we found that the increased levels of phosphorylated ERK1/2 in colorectal cancer HCT-116 cells were inhibited by YQFS in a dose-dependent manner. We also found that p38 and JNK1/2 were activated in colorectal cancer HCT-116 cells even though their activation levels differed. However, YQFS failed to inhibit phosphorylation of p38 and JNK1/2 in HCT-116 cells suggesting that YQFS might selectively target the ERK signaling pathway.To further investigate the general effect of YQFS on colorectal cancer, we examined the effect of YQFS treatment in vivo. Our results are consistent with previous in vivo studies, where YQFS inhibited colorectal tumor growth compared with the control group in a dose-dependent manner. Furthermore, we found that chronic treatment with YQFS induced a significant increase in apoptosis in colorectal tumors, as judged by TUNEL staining. These results are consistent with studies performed by Gexia-Zhuyu Tang who showed that HSC apoptosis was induced via caspase 3[].Within the past few years, many researchers have demonstrated the importance of MMPs in malignant transformation. MMP activity has been implicated in almost every stage of the metastatic cascade from the primary site to the progression of tumor-extravasation,- growth and -development. MMPs are enzymes that degrade structural components of the extra cellular matrix. These enzymes regulate a multitude of physiological processes such as morphogenesis, tissue remodeling and signaling events. Numerous studies have demonstrated a strong correlation between MMP-2/9 expression and migration/invasion in human colorectal cancer cells. In this study, we found a downregulation in MMP-2/9 expression following exposure to YQFS in rat colorectal tumors. These results are consistent with previous studies that evaluated the effects of MMP-2/9 inhibition on the suppression of tumor migration/invasion[].In recent years, there is increasing evidence to support the role of MMPs in mediating many changes in the tumor microenvironment during malignant transformation. Importantly, MAP kinase signaling such as ERK, JNK, p38, plays a significant role in MMP regulation, particularly MMP-2/9 in tumor cell migration. In this study, we observed that activation of the ERK pathway correlated with an increased expression of MMP-2/9. However, YQFS significantly reduced levels of p-ERK thus inhibiting the ERK pathway.YQFS is the standard formulation of Si-Jun-Zi-Tang with the addition of Rou-dou-kou (Myristica fragrans) and Ba-yue-zha (Fiveleaf Akebia fruit) to create another formula known as Yi-Qi-Fu-Sheng-Fang. It was recently reported that Rou-dou-kou (Myristica fragrans), had a significant inhibitory effect on the growth of a colorectal cancer cell line[]. Furthermore, Ba-yue-zha (Fiveleaf Akebia fruit), has been shown to remove toxic materials to inhibit tumor growth, and activate blood circulation to dissipate blood stasis[, ], and to improve patients’ survival quality in 60 cases of intermediate and advanced malignant tumors[]. In addition, previous studies have shown that Si-Jun-Zi-Tang can lessen the degree of post-operational stress and inflammatory response, and enhance the immune function of patients during enteral nutritional therapy[]. In vivo studies have shown that SJZD can prevent indomethacin-induced damage of intestinal epithelial cells by inhibiting migration and proliferation of IEC-6 cells[]. These results therefore strongly support the protective effects of YQFS against human colorectal cancer.In conclusion, the present study served to confirm the antitumor effects of YQFS in vitro and in vivo. Our results indicate that the therapeutic effect of YQFS may be explained by the inhibition of ERK-dependent migration/invasion. In addition, clarification of the underlying mechanism of YQFS will provide new anti-cancer therapeutic targets.The authors thank Prof. Qi Li for his support. This work was funded by the Natural Science Foundation of Xinjiang Uygur Autonomous Region
and the National Natural Science Foundation of China (No.).The authors declare that they have no competing interests.WLD and ML carried out the study and designed the experiments. QIW, NNH, and CYD contributed reagents, materials, and analysis tools. LH analyzed data. HS contributed the animal model. All authors read and approved the final manuscript.
(148 kb) Authors’ original file for figure 1
(2.8 mb) Authors’ original file for figure 2
(3.4 mb) Authors’ original file for figure 3
(196 kb) Authors’ original file for figure 4
(357 kb) Authors’ original file for figure 5
(1.9 mb) Authors’ original file for figure 6
(129 kb) Authors’ original file for figure 7
(121 kb) Authors’ original file for figure 8
1.Shaffer VA, Merkle EC, Fagerlin A, Griggs JJ, Langa KM, Iwashyna TJ: Chemotherapy was not associated with cognitive decline in older adults with breast and colorectal cancer: findings from a prospective cohort study. Med Care. 9-855. 10.1097/MLR.0b013e.2.Mok TS, Yeo W, Johnson PJ, Hui P, Ho WM, Lam KC, Xu M, Chak K, Chan A, Wong H, Mo F, Zee B: A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity. Ann Oncol. 8-774.3.Barnes PM, Powell-Griner E, McFann K, Nahin RL: Complementary and alternative medicine use among adults: United States 2002. Adv Data. : 1-19.4.Duan P, Wang ZM: Clinical study on effect of Astragalus in efficacy enhancing and toxicity reducing of chemotherapy in patients of malignant tumor. Chin J Integr Med. 5-517.5.Ye Y, Chou GX, Mu DD, Wang H, Chu JH, Leung AK, Fong WF, Yu ZL: Screening of Chinese herbal medicines for antityrosinase activity in a cell free system and B16 cells. J Ethnopharmacol. : 387-390. 10.1016/j.jep..6.JY, Richardson BC: The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 2-327. 10.-68-6.7.Troppmair J, Bruder JT, Munoz H, Lloyd PA, Kyriakis J, Banerjee P, Avruch J, Rapp UR: Mitogen-activated protein kinase extracellular signal-regulated protein kinase activation by oncogenes, serum, and 12-O-tetradecanoylphorbol-13-acetate requires Raf and is necessary for transformation. J Biol Chem. : .8.Sui H, Li Q: Mechanism research of JNK/SAPK signal transduction pathway and multidrug resistance, Cancer Research on prevention and treatment. Cancer Research on Prevention and Treatment. 4-847.9.Babykutty S, Suboj P, Srinivas P, Nair AS, Chandramohan K, Gopala S: Insidious role of nitric oxide in migration/invasion of colon cancer cells by upregulating MMP-2/9 via activation of cGMP-PKG-ERK signaling pathways. Clin Exp Metastasis. 1-492. 10.-012-9464-6.10.Zhang Y, Li PP: Shu-Gan-Liang-Xue Decoction, a Chinese herbal formula, down-regulates the expression of steroid sulfatase genes in human breast carcinoma MCF-7 cells. J Ethnopharmacol. : 620-624. 10.1016/j.jep..11.Marchbank T, Ojobo E, Playford CJ, Playford RJ: Reparative properties of the traditional Chinese medicine Cordyceps sinensis (Chinese caterpillar mushroom) using HT29 cell culture and rat gastric damage models of injury. Br J Nutr. : . 10..12.McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. : 1-6. 10.1056/NEJM101.13.Huang XC, Yu XH, Chen JH: Effects of Sijunzitang on Cellular Immune Functions of Colorectal Cancerous Persons with Neoadjuvant Chemotherapy. Journal of Snake. -25.14.Piras A, Rosa A, Marongiu B, Atzeri A, Dessì MA, Falconieri D, Porcedda S: Extraction and separation of volatile and fixed oils from seeds of Myristica fragrans by supercritical CO2: chemical composition and cytotoxic activity on Caco-2 cancer cells. J Food Sci. 2012, 77: C448-453. 10.1111/j.12.02618.x.15.Cheng JH: Discussion on Syndrome Differentiation and Treatment of Intestinal Cancer. New journal of Traditional Chinese Medicine. -4.16.Sun Z, Su YH, Yue XQ: Professor Ling Changquan’s experience in treating primary liver cancer: an analysis of herbal medication. Zhong Xi Yi Jie He Xue Bao. 21-6/jcim.17.Zhao FR, Mao HP, Zhang H, Hu LM, Wang H, Wang YF, Yanagihara N, Gao XM: Antagonistic effects of two herbs in Zuojin Wan, a traditional Chinese medicine formula, on catecholamine secretion in bovine adrenal medullary cells. Phytomedicine. 9-668. 10.1016/j.phymed..18.Wynne S, Djakiew D: NSAID inhibition of prostate cancer cell migration is mediated by Nag-1 Induction via the p38 MAPK-p75(NTR) pathway. Mol Cancer Res. 56-8/.MCR-10-0342.19.Sui H, Zhou SF, Wang Y, Liu X, Zhou LH, Yin PH, Fan ZZ, Li Q: COX-2 contributes to P-glycoprotein-mediated multidrug resistance via phosphorylation of c-Jun at Ser63/73 in colorectal cancer. Carcinogenesis. 7-675. 10.1093/carcin/bgr016.20.Kolinsky K, Shen BQ, Zhang YE, Kohles J, Dugan U, Zioncheck TF, Heimbrook D, Packman K, Higgins B: In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models. Mol Cancer Ther. -82.21.Yee YK, Tan VP, Chan P, Hung IF, Pang R, Wong BC: Epidemiology of colorectal cancer in Asia. J Gastroenterol Hepatol. 10-1/j.09.06138.x.22.Kang GH: Four molecular subtypes of colorectal cancer and their precursor lesions. Arch Pathol Lab Med. : 698-703.23.Hseu YC, Wu CR, Chang HW, Kumar KJ, Lin MK, Chen CS, Cho HJ, Huang CY, Huang CY, Lee HZ, Hsieh WT, Chung JG, Wang HM, Yang HL: Inhibitory effects of Physalis angulata on tumor metastasis and angiogenesis. J Ethnopharmacol. : 762-771. 10.1016/j.jep..24.Sui H, Fan ZZ, Li Q: Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells. J Int Med Res. 6-435. 10..25.VanZomeren-Dohm A, Sarro J, Flannery E, Duman-Scheel M: The Drosophila Netrin receptor frazzled/DCC functions as an invasive tumor suppressor. BMC Dev Biol. -10.3X-11-41.26.Chen JY, Chen HL, Cheng JC, Lin HJ, Tung YT, Lin CF, Chen CM: A Chinese herbal medicine, Gexia-Zhuyu Tang (GZT), prevents dimethylnitrosamine-induced liver fibrosis through inhibition of hepatic stellate cells proliferation. J Ethnopharmacol. : 811-818. 10.1016/j.jep..27.Babykutty S, PP S, NR J, Kumar MA, Nair MS, Srinivas P, Gopala S: Nimbolide retards tumor cell migration, invasion, and angiogenesis by downregulating MMP-2/9 expression via inhibiting ERK1/2 and reducing DNA-binding activity of NF-κB in colon cancer cells. Mol Carcinog. 5-490. 10.1002/mc.20812.28.Wu JP, Li Y, Feng N, Bei LM: Influence of Compound Sargentgloryvine Granule on living quality of patients treated by actinotherapy and chemotherapy. Traditional Chinese Medicinal research. -18.29.Liang C, Zhang SH, Cai ZD: Effects of early intestinal application of sijunzi decoction on immune function in post-operational patients of gastrointestinal tumor. Zhongguo Zhong Xi Yi Jie He Za Zhi. 70-1073.30.Liu L, Han L, Wong DY, Yue PY, Ha WY, Hu YH, Wang PX, Wong RN: Effects of Si-Jun-Zi decoction polysaccharides on cell migration and gene expression in wounded rat intestinal epithelial cells. Br J Nutr. -29. 10.1079/BJN.The pre-publication history for this paper can be accessed here:
Wanli Deng1Hua Sui2Qiaolin Wang1Nana He1Chunyan Duan1Liang Han1Qi Li3Ming Lu1Shuqin Lv11.Oncology Department I of Traditional Chinese Medical Hospital of Xinjiang Uygur Autonomous RegionXinjiangChina2.Department of Medical OncologyShuguang Hospital, Shanghai University of Traditional Chinese MedicineShanghaiChina3.Interventional Cancer Institute of Integrative Medicine &Putuo Hospital, Shanghai University of Traditional Chinese MedicineShanghaiChina